(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 3 284 519 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see Bibliography
Remarks

(48) Corrigendum issued on:
18.04.2018 Bulletin 2018/16

(43) Date of publication:
21.02.2018 Bulletin 2018/08

(21) Application number: **17195276.5**

(22) Date of filing: **28.04.2006**

(51) Int Cl.:
A61P 31/18 *(2006.01)* ***A61K 31/4985*** *(2006.01)*
C07D 498/04 *(2006.01)*

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: **28.04.2005 JP 2005131161**
27.10.2005 JP 2005312076

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
16154531.4 / 3 045 206
12159079.8 / 2 527 007
06758843.4 / 1 874 117

(71) Applicants:
- **VIIV Healthcare Company**
  Wilmington, DE 19808 (US)
- **Shionogi & Co., Ltd**
  Osaka-shi, Osaka 541-0045 (JP)

(72) Inventors:
- **JOHNS, Brian Alvin**
  Research Triangle Park, NC North Carolina 27709 (US)
- **KAWASUJI, Takashi**
  Toyonaka, Osaka 561-0825 (JP)
- **TAISHI, Teruhiko**
  Kita-ku, Osaka 530-0012 (JP)
- **TAODA, Yoshiyuki**
  Toyonaka-shi, Osaka 561-0825 (JP)

(74) Representative: **J A Kemp**
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

Remarks:
•Amended claims in accordance with Rule 137(2) EPC.
•This application was filed on 06-10-2017 as a divisional application to the application mentioned under INID code 62.

(54) **POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY**

(57) The present invention is to provide a novel compound (I-1) shown below, having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof.



(I

wherein

Printed by Jouve, 75001 PARIS (FR)

(Cont. next page)

A ring is substituted ring of (a), (b) or (c)



(a)



(b)

wherein Z is O or NR^{19},
R^{19} is hydrogen, C_{1-10}alkyl, C_{2-8}alkenyl, C_{1-10}alkylcarbonyl or C_{1-10}alkylsulfonyl, and the other substituents on the A ring form a ring;
R^{14} and R^X are hydrogen;
a broken line represents the presence or absence of a bond, provided that when the broken line represents the presence of a bond, R^X is not present;
R^1 is hydrogen or C_{1-10}alkyl;
X is C_{1-6}alkylene;
R^2 is phenyl or phenyl substituted with at least halogen;
R^3 is hydrogen, halogen, hydroxy, C_{1-10}alkyl, C_{2-8}alkenyl, C_{1-10}alkoxy, C_{2-8}alkenyloxy or amino;
or a pharmaceutically acceptable salt, or solvate thereof.